Bristol-Myers Squibb Co BMY is trading higher Monday after the company announced an additional $15 billion buyback and raised its quarterly dividend.
Bristol-Myers authorized the repurchase of an additional $15 billion of the company’s common stock. With this increase, the company’s total outstanding share repurchase authorization is approximately $15.2 billion. Management can execute repurchases at its discretion.
The company declared a quarterly dividend of 54 cents per share, representing a 10.20% increase year-over-year. This marks the 13th consecutive fiscal year that Bristol-Myers has increased its dividend.
"The company’s financial position is strong, and we remain committed to a consistent, balanced capital allocation strategy," said Giovanni Caforio, board chair and CEO of Bristol-Myers.
See Also: Where Bristol-Myers Squibb Stands With Analysts
Bristol-Myers discovers, develops and markets drugs for various therapeutic areas, such as cardiovascular, oncology and immune disorders.
BMY Price Action: Bristol-Myers has traded as high as $69.75 and as low as $53.22 over a 52-week period.
The stock was up 4.07% at $58.66 at time of publication.
Photo: A 4 from Flickr.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.